Ghent University Academic Bibliography

Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur)

Veerle Casneuf, Ivan Borbath, Marc Van den Eynde, Yolanda Verheezen, Wim Demey, Alain Verstraete (UGent) , Kathleen Claes (UGent) , Vincent Haufroid and Karen Geboes (UGent)

(2022) ACTA CLINICA BELGICA. 77(2). p.346-352

Add to list

Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms : a Belgian national study

Bruno Waked, Filip De Maeyer, Saskia Carton, Pieter-Jan Cuyle, Timon Vandamme, Chris Verslype, Pieter Demetter, Ivan Borbath, Liesbet Van Eycken, Anne Hoorens (UGent) , et al.

(2022) ACTA CLINICA BELGICA. 77(5). p.823-831

Add to list

Journal Article
A1
open access

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma : data from the open-label, phase II KEYNOTE-224 trial

Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe (UGent) , Adel Kardosh, Vittorina Zagonel, Per Stal, Debashis Sarker, Daniel H. Palmer, et al.

(2022) CLINICAL CANCER RESEARCH. 28(12). p.2547-2554

Add to list

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

Nicola Personeni, Laura Giordano, Giovanni Abbadessa, Camillo Porta, Ivan Borbath, Bruno Daniele, Jean-Luc Van Laethem, Hans Van Vlierberghe (UGent) , Joerg Trojan, Enrico N. De Toni, et al.

(2017) ONCOTARGET. 8(9). p.14408-14415

Add to list

Journal Article
A1
open access

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Lorenza Rimassa, Giovanni Abbadessa, Nicola Personeni, Camillo Porta, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean-Luc Van Laethem, Hans Van Vlierberghe (UGent) , Jörg Trojan, et al.

(2016) ONCOTARGET. 7(45). p.72622-72633

Add to list

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digstive Oncology

Ivan Borbath, Antonio Ceratti, Chris Verslype, Anne Demols, Thierry Delaunois, Stéphanie Laurent (UGent) , Anne Deleporte, Peter Vergauwe, A Van Maanen, Christine Sempoux, et al.

(2013) ANNALS OF ONCOLOGY. 24(11). p.2824-2829

Add to list

Journal Article
A1
open access

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

Alain Hendlisz, Vassilis Golfinopoulos, Amelie Deleporte, Marianne Paesmans, Hazem El Mansy, Camilo Garcia, Marc Peeters, Lieven Annemans (UGent) , Caroline Vandeputte, Marion Maetens, et al.

(2013) BMC CANCER. 13.

Add to list

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean Luc Van Laethem, Hans Van Vlierberghe (UGent) , Jörg Trojan, Frank T Kolligs, Alan Weiss, et al.

(2013) LANCET ONCOLOGY. 14(1). p.55-63

Add to list

Conference Paper
C3
open access

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study

Ivan Borbath, Antonio Ceratti, Chris Verslype, Anne Demols, Thierry Delaunois, Stéphanie Laurent (UGent) , Amélie Deleporte, Philippe Vergauwe, Eric Van Cutsem and Jean-Luc Van Laethem

(2011) JOURNAL OF CLINICAL ONCOLOGY. 29(4, suppl.).

Add to list

Sorafenib in advanced hepatocellular carcinoma

Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frederic Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, et al.

(2008) NEW ENGLAND JOURNAL OF MEDICINE. 359(4). p.378-390

Academic Bibliography

Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur)

Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms : a Belgian national study

Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma : data from the open-label, phase II KEYNOTE-224 trial

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digstive Oncology

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study

Sorafenib in advanced hepatocellular carcinoma

Contents

Support

Contact